Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review
Thoracic Cancer · 2023-10 · 14 (28) · 2886-2889
DOI: 10.1111/1759-7714.15081 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thoracic Cancer, online erschienen am 28.08.2023. Verfasst von Chihiro Maeda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Among epidermal growth factor receptor ( EGFR ) mutation‐positive non‐small cell lung cancers, squamous cell carcinoma is less common and shows lower responsiveness to first‐generation EGFR tyrosine kinase inhibitors (TKIs) compared to adenocarcinoma. However, the efficacy of osimertinib for squamous cell carcinoma with EGFR mutations is not well known. This study reports the case of a 57‐year‐old male diagnosed as having stage IIIC squamous cell lung cancer. Oncomine Dx Target Test identified EGFR exon19 deletion and de novo EGFR T790M mutation with variant allele frequencies (VAF) of 21.6% and 25.2%, respectively. The patient was treated with osimertinib after progression on chemoradiotherapy followed by durvalumab, and a partial response was maintained for more than 20 months. To predict EGFR‐TKI efficacy, confirmation of gene mutations and VAF using next‐generation sequencing is helpful.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
- Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.
ORCID-Profile: Kanako Shinada, Shuji Murakami, Haruhiro Saito
Zitieren
APA
Maeda, C., Shinada, K., Murakami, S., & Saito, H. (2023). Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review. Thoracic Cancer, 14(28), 2886-2889. https://doi.org/10.1111/1759-7714.15081
Vancouver
Maeda C, Shinada K, Murakami S, Saito H. Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review. Thoracic Cancer. 2023;14(28):2886-2889. doi:10.1111/1759-7714.15081
BibTeX
@article{Maeda2023,
author = {Maeda, Chihiro and Shinada, Kanako and Murakami, Shuji and Saito, Haruhiro},
title = {Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review},
journal = {Thoracic Cancer},
year = {2023},
volume = {14},
number = {28},
pages = {2886--2889},
doi = {10.1111/1759-7714.15081}
}
EUVIMED